The U.S. is considering adopting foreign price controls for prescription drugs—a move that could backfire, U.S. Chamber Executive Vice President Neil Bradley writes in an op-ed for IPWatchdog.
Why it matters: Tying American medicine prices to those set by other countries risks choking off the innovation pipeline that brings new, life-saving treatments to market.
Be smart: Free market policies—backed by strong intellectual property—drive investment, research, and access to breakthrough medicines. Price controls put medical progress at risk.